This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Click here for Trumenba®▼ (meningococcal group B vaccine (recombinant, adsorbed)) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

Meningococcal group B vaccine

Trumenba (meningococcal group B vaccine (recombinant, adsorbed)) is indicated for active immunisation of individuals 10 years and older to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B1

Trumenba is a vaccine composed of 2 recombinant lipidated factor H binding protein (fHbp) variants. fHbp is found on the surface of meningococcal bacteria and is essential for bacteria to avoid host immune defences.1
fHbp variants segregate into 2 immunologically distinct subfamilies, A and B, and over 91%** of MenB strains express sufficient levels of fHbp subfamily A or B to  be killed by Trumenba induced antibodies1
Vaccinate with Trumenba to help protect adolescents and young adults from MenB disease.1

**A survey of over 2,150 different invasive meningococcal serogroup B isolates collected from 2000-2014 in 7 European countries, the US and Canada demonstrated that over 91% of all meningococcal serogroup B isolates expressed sufficient levels of fHbp to be susceptible to bactericidal killing by vaccine-induced antibodies.1​​​​​​​
​​​​​​​

Trumenba offers two dosing schedules for adolescents and young adults1

Dosing Schedules

2-dose schedule1
This includes 2 doses (0.5ml each) administered 6 months apart.

3-dose schedule1
This includes 2 doses (0.5ml each) administered at least 1 months apart, followed by a third dose at least 4 months after the second dose.


Dosing considerations1

  • A booster dose should be considered following either dosing regimen for individuals at continued risk of IMD.
  • The use of this vaccine should be in accordance with official recommendations1

Trumenba can be co-administered concomitantly with​​​​​​​1 :

  • Quadrivalent Human Papillomavirus vaccine (HPV4)
  • Meningococcal Serogroups A, C, W, Y conjugate vaccine (MenACWY)
  • Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed (Tdap)
  • Tetanus Toxoid, Reduced Diphtheria Toxoid, Acellular Pertussis, and Inactivated Poliovirus Vaccine (TdaP-IPV)
References​​
  1. Trumenba. Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/2670​​​​​​​
PP-TRU-GBR-0130. March 2021

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No